RTI Surgical & Aziyo Biologics ink deal: 4 things to know

Written by Shayna Korol | August 02, 2018 | Print  |

Aziyo Biologics will exclusively distribute its bone repair product ViBone through RTI Surgical in the U.S.

Here are four things to know:

1. ViBone is a next-generation viable bone matrix designed to perform and handle more closely to autograft.

2. Aziyo Biologics processes ViBone using a proprietary method intended to protect the native tissue environment to potentially enhance new bone formation.

3. RTI Surgical will incorporate ViBone into its U.S. sales and growth strategy, effective immediately.

4. RTI Surgical and Aziyo Biologics will initiate new research on ViBone.

"This agreement provides a platform for RTI and Aziyo to mutually grow and expand in the spinal fusion and orthopedic markets in service to more patients," said Aziyo Biologics' president and CEO Ron Lloyd.

More articles on biologics:
Asterias Biotherapeutics' stem cell-derived treatment for spinal cord injury holds promise: 4 things to know
Ortho RTi receives extension on 2.1M+ warrants: 3 observations
Appalachian Orthopedics' surgeons perform cartilage restoration procedures: 3 insights

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months